Cited by 729Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Open access

Lenz, Heinz-Josef, Van Cutsem, Eric, Luisa Limon, Maria, Wong, Ka Yeung Mark, Hendlisz, Alain, Aglietta, Massimo, García-Alfonso, Pilar, Neyns, Bart, Luppi, Gabriele, Cardin, Dana B., Dragovich, Tomislav, Shah, Usman, Abdullaev, Sandzhar, Gricar, Joseph, Ledeine, Jean-Marie, Overman, Michael James, Lonardi, Sara·2022·Journal of Clinical Oncology

DOI 10.1200/jco.21.01015

Open this paper in CoChat — free account Open PDF

Abstract

PURPOSE: Nivolumab received US Food and Drug Administration approval as a single agent or in combination with ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) that progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan based on CheckMate 142. Presented are results of nivolumab plus low-dose ipilimumab in the first-line therapy cohort from the phase II CheckMate 142 study. PATIENTS AND METHODS: Patients with no prior treatment in the metastatic setting for MSI-H/dMMR CRC were treated with nivolumab every 2 weeks plus low-dose ipilimumab every 6 weeks until disease progression. The primary end point was objective response rate (investigator assessment; RECIST v1.1). RESULTS: Median age of treated patients was 66 years (N = 45). Median follow-up was 29.0 months. Objective response rate and disease control rate were 69% (95% CI, 53 to 82) and 84% (95% CI, 70.5 to 93.5), respectively, with 13% complete response rate. Median duration of response was not reached; 74% of responders had ongoing responses at data cutoff. Median progression-free survival and median overall survival were not reached with minimum follow-up of 24.2 months (24-month rates, 74% and 79%, respectively). Clinical benefit was observed regardless of baseline demographic and tumor characteristics, including BRAF or KRAS mutation status. In a post hoc analysis, of 14 patients who discontinued treatment and did not receive subsequent therapy, 10 remained progression-free. Patient-reported outcomes were stable over the treatment period. Grade 3-4 treatment-related adverse events occurred in 22% of patients; 13% discontinued because of any-grade treatment-related adverse events. CONCLUSION: Nivolumab plus low-dose ipilimumab demonstrated robust and durable clinical benefit and was well tolerated as a first-line treatment for MSI-H/dMMR mCRC. Based on these promising data, randomized studies are warranted.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.21.01015

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Colorectal cancer statistics, 2017
Siegel, R. L., Miller, K. D., Fedewa, S. A., Ahnen, D. J., Meester, R. G. S., Barzi, A., & Jemal, A. (2017) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21395 · Cited by 3,807
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Brahmer, J. R., Lacchetti, C., Schneider, B. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Ernstoff, M. S., Gardner, J. M., Ginex, P., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6385 · Cited by 3,713

Flagged first, then by citations

Show all 30 references

Research works printed but not linked: 3

2020, Opdivo (nivolumab) Injection for Intravenous Use [prescribing information]
National Comprehensive Cancer Network, Colon Cancer (Version 2.2021)
National Comprehensive Cancer Network, Rectal Cancer (Version 1.2021)

Sorted by citations

Items 401–500 of 729

Immune checkpoint inhibitor therapy in neoadjuvant and adjuvant treatment for cancer: A paradigm shift in the treatment of resectable gastrointestinal cancer 3)A paradigm shift in the treatment of colorectal cancer
Oshima, K., & Yamazaki, K. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02387-x · Cited by 4
Efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer according to programmed cell death ligand 1
Kang, S. W., Lim, S. H., Kim, M., Lee, J., Park, Y. S., Lim, H. Y., Kang, W. K., & Kim, S. T. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i8.3521 · Cited by 4
Systemic treatment of mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer—single versus double checkpoint inhibition
Marinelli, D., Sabatini, A., Bengala, E., Ciurluini, F., Picone, V., Santini, D., Pietrantonio, F., Rossini, D., & Cremolini, C. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103483 · Cited by 4
Immune-checkpoint inhibitor resistance in patients with cancer
Cabezón‐Gutiérrez, L., Custodio‐Cabello, S., Palka-Kotlowska, M., Chacón-Ovejero, B., & Pacheco-Barcía, V. (2025) · Exploration of Immunology · doi:10.37349/ei.2025.1003196 · Cited by 4
Is neoadjuvant immunotherapy feasible for patients with dMMR/MSI−H locally advanced colorectal cancer? a retrospective study
Luo, Z., Wang, D., Wang, Z., Zhao, H., & Xiang, R. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1645412 · Cited by 3
Treatment with checkpoint inhibitors for unresectable non-metastatic mismatch repair deficient intestinal cancer; a case series
Figaroa, O., Spaanderman, I. T., Goedegebuure, R. S. A., Cirkel, G. A., Jeurissen, F. J. F., Creemers, G. J., Bins, A. D., Tuynman, J. B., & Buffart, T. E. (2025) · BJC Reports · doi:10.1038/s44276-025-00171-0 · Cited by 3
Immunotherapy versus chemotherapy as adjuvant therapy for resected MSI-H/dMMR colorectal cancer: real-world evidence informing precision strategies
Sun, H., Lyu, P., Yang, S., Wang, F., Zhai, S., Zhao, M., Yuan, W., & Zhou, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664684 · Cited by 3
Germline Mutations as Cancer Drug Targets
Tang, T., Maresso, K. C., Ngeow, J. Y. Y., Vilar, E., & Yap, T. A. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-1241 · Cited by 3
Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review
Wei, C., Tang, C., Zhang, Y., Tang, Y., Liu, D., Tan, Y., & Fu, Y. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05412-1 · Cited by 3
Safety and Efficacy of Nivolumab Plus Ipilimumab in Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Cancer: A Systematic Review
Kokori, E., Abraham, I. C., Olatunji, G. D., Aboje, J. E., Akinruli, O. A., Joseph, S. A., Agyemang, E. A., Ezeano, C., Bukky, S. O., Aderinto, N., et al. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.104028 · Cited by 3
The TP53-LGALS4 axis modulates the tumor immune microenvironment and synergizes with anti PD-L1 therapy in colorectal cancer
Zhang, F., Yang, M., Peng, X., Qin, Q., Huang, Y., Deng, R., Zhang, D., Zhang, L., Liang, H., & Li, J. W. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07598-6 · Cited by 3
Ensemble learning for predicting microsatellite instability in colorectal cancer using pretreatment colonoscopy images and clinical data
You, J., Zhang, S., Zhang, J., Chen, Y., Zhang, M., Zhou, C., & Jiang, B. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1734076 · Cited by 3
Discovery and Preclinical Evaluations of Potent, Selective, and Allosteric Covalent WRN Inhibitors with Improved PK Properties
Xu, Z., Xiao, Q., Liu, Y., Jiang, W., Liu, L., Sun, H., Yang, X., Lu, Z., Yan, B., Long, H., et al. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00787 · Cited by 3
Tislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study
Liu, X., Ou, K., Ma, X., Yang, W., Cao, B., Lu, J., Zhang, L., Gao, L., Wang, Q., Zhang, W., et al. (2026) · ESMO Open · doi:10.1016/j.esmoop.2025.106056 · Cited by 3
Rare, Yet Targetable: New Perspectives on Ampullary Carcinomas
Gutmans, J., Friedlaender, A., & Mechahougui, H. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031597 · Cited by 3
Epigenetic and mitoepigenetic regulation in cancer and therapeutic perspectives
Uzuner, S. Ç., Nalkıran, İ., Uzuner, U., & Nalkıran, H. S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1760013 · Cited by 3
Bridging clinical gaps in personalized cancer neoantigen vaccines
Khaddour, K., & Ott, P. A. (2026) · Cancer Cell · doi:10.1016/j.ccell.2026.04.002 · Cited by 4
Oat-β-glucan potentiates anti-PD-1 efficacy through Faecalibacterium prausnitzii-derived butyrate and indole-3-propionic acid
Yang, S., Lu, H., Jin, M., Pei, W., Wang, Z., Ni, J., Shi, Y., Zhang, S., Li, Y., Li, C., et al. (2026) · Cell Host & Microbe · doi:10.1016/j.chom.2026.05.002 · Cited by 4
Case report: A case of complete clinical response in a patient experiencing high microsatellite instability unresectable colon cancer being treated with a PD-L1 inhibitor after interstitial pneumonia
Wang, L., Mou, H., Hou, X., & Liao, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1126769 · Cited by 3
Stage IV Colorectal Cancer at Initial Presentation versus Progression during and after Treatment, Differences in Management: Management Differences for Initial Presentation versus Progression of Disease after Initial Treatment
Monahan, B. V., Patel, T., & Poggio, J. L. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1761626 · Cited by 3
Tumor cell stemness in gastrointestinal cancer: regulation and targeted therapy
Yang, K., & Yi, T. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1297611 · Cited by 5
Metastatic colorectal cancer- third line therapy and beyond
Foo, T., Roy, A. C., Karapetis, C. S., Townsend, A. R., & Price, T. J. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2334784 · Cited by 3
Clinical and Molecular Variables Associated With Early Progression to Checkpoint Inhibitors in MSI-High Metastatic Colorectal Cancer: A Retrospective Cohort Study
Hulst, L. A., Cappuyns, S., Peeters, F., Vulsteke, F., Herpe, F. V., Cutsem, E. V., & Dekervel, J. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.06.004 · Cited by 3
Improved survival with immunotherapy for microsatellite unstable colorectal cancer with peritoneal metastases
Khorfan, R., Sedighim, S., Caba‐Molina, D., Tran, T. B., Senthil, M., O'Leary, M. P., & Eng, O. S. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27740 · Cited by 3
Current Status of Chemotherapy in Colorectal Cancer: Updated Treatment Strategies
Kim, J. H., & Park, S. J. (2024) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2024.087 · Cited by 3
Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastro-oesophageal junction adenocarcinoma: study protocol for a single-arm, phase II clinical trial
Zhang, P.-F., Zhang, W.-H., Liu, X.-J., He, D., Yang, K., Gou, H., & Hu, J. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081529 · Cited by 3
Spatiotemporal T-cell tracking for personalized T-cell receptor T-cell therapy designs in childhood cancer
Sentís, I., Melero, J. L., Cebria‐Xart, A., Grzelak, M., Soto, M., Michel, A., Rovira, Q., Rodríguez-Hernández, C. J., Caratù, G., Urpi, A., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.530 · Cited by 4
Immunotherapy in Gastrointestinal Cancers: Current Insights
Jiang, X., Zhan, Y., Yang, D., & Bao, L. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497836 · Cited by 3
Immunotherapy-Induced Complete Response in dMMR Rectal Cancer—A Surgical Dilemma?
Loufopoulos, P. D., Perivoliotis, K., Chatziathanasiou, D., Frountzas, M., Sukha, A., Alrebdi, A., Eddama, M. M. R., Kontovounisios, C., Qiu, S., Tekkis, P. P., et al. (2025) · Cancers · doi:10.3390/cancers17193153 · Cited by 3
Comprehensive exploration of tumor immune microenvironment feature and therapeutic response in colorectal cancer based on a novel immune-related long non-coding RNA prognostic signature
Zhou, X., Aikemu, B., Li, S., Shao, Y., Jia, H., Huang, L., Hong, H., Zhang, S., Tang, Q., Pan, R., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.962575 · Cited by 3
Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement
Grávalos, C., Pereira, F., Vera, R., Arjona‐Sánchez, Á., Losa, F., Ramos, I., Alfonso, P. G., Bayón, L. G., Cascales-Campos, P. A., & Aranda, E. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03204-7 · Cited by 4
Broad spectrum integrin inhibitor GLPG-0187 bypasses immune evasion in colorectal cancer by TGF-β signaling mediated downregulation of PD-L1.
MacDonald, W. J., Verschleiser, B., Carlsen, L., Huntington, K. E., Zhou, L., & El‐Deiry, W. S. (2023) · PubMed Central · Cited by 3
Case report: Efficacy of immunotherapy as conversion therapy in dMMR/MSI-H colorectal cancer: a case series and review of the literature
Román, M. S., Martínez-Delfrade, Í., Albarrán, V., Guerrero-Serrano, P., Pozas, J., Chamorro-Pérez, J., Rodriguez, D. I. R., Sotoca-Rubio, P., Barrill-Corpa, A. M., Navarro, V., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1352262 · Cited by 3
Effectiveness of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors in patients with advanced or metastatic colorectal carcinoma with either mismatch repair proficient or metastatic microsatellite stable disease: A systematic review and meta‑analysis
Li, J., Zhu, J., Zhang, Y., & Li, S. (2024) · Oncology Letters · doi:10.3892/ol.2024.14286 · Cited by 3
Conversion therapy with pembrolizumab for a peritoneal metastasis of rectal cancer causing hydronephrosis in a patient with Lynch syndrome
Matsumoto, A., Shimada, Y., Nakano, M., Ozeki, H., Yamai, D., Murata, M., Ishizaki, F., Nyuzuki, H., Ikeuchi, T., & Wakai, T. (2024) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-024-01931-0 · Cited by 3
Immune-mediated hepatitis: Basic concepts and treatment
Velasco, J. A. V.-R., Calderón, D. K. T., Cerpa‐Cruz, S., Chávez, J. A. V., Martínez, J. F. U., García-Jiménez, E. S., Ledesma, J. M. A., Díaz‐González, Á., & Crespo, J. (2024) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2023.12.001 · Cited by 3
The impact of time to surgery on oncological outcomes in stage I-III dMMR colon cancer – A nationwide cohort study
Justesen, T. F., Gögenur, M., Clausen, J. S. R., Mashkoor, M., Rosen, A. W., & Gögenür, I. (2023) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2023.03.223 · Cited by 3
Immunotherapy for Colorectal Cancer
Zhang, C., COX, R. A., & Chakrabarti, S. (2025) · Springer eBooks · doi:10.1007/978-3-030-80962-1_220-1 · Cited by 3
Immunotherapy in Localized Microsatellite Instability–High/Mismatch Repair Deficient Solid Tumors: Are We Ready for a New Standard of Care?
Ciombor, K. K., & Eng, C. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02564 · Cited by 3
The Use of Dostarlimab, a Safe and Efficient Monotherapy in Msi-H Rectal Cancer Patients, an Alternative to Surgery
Baz, Y., Rassam, M., Rhayem, E., Zouein, J., Gharios, J., & Kourié, H. R. (2023) · Immunotherapy · doi:10.2217/imt-2022-0239 · Cited by 3
Comparative efficacy of PD-1 blockade in patients with dMMR/MSI-H metastatic colorectal or gastric cancer: a global retrospective study
Mazzoli, G., Nichetti, F., Shitara, K., Cohen, R., Lonardi, S., Cremolini, C., Elez, M. E., Chao, J., Fakih, M., Klempner, S. J., et al. (2024) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2023.100037 · Cited by 2
Self-citation
SOX17 : a new therapeutic target for immune evasion of colorectal cancer
Das, A., Yilmaz, Ö. H., Yilmaz, O. H., & Deshpande, V. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-209878 · Cited by 2
Mismatch repair deficiency/microsatellite instability (dMMR/MSI-H) in rectal cancer patients treated with standard neoadjuvant therapy: a systematic review and meta-analysis
Ricco, G., Gallio, C., Benhima, N., Assaf, I., Laethem, J. V., & Sclafani, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103039 · Cited by 2
Accuracy of Deep Learning-Aided Detection of Microsatellite Instability in Colorectal Cancer: A Systematic Review and Meta-Analysis
Wang, Z., Chang, F., Wu, H., Yuan, X., Chen, Y., & Han, J. (2025) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2025.09.004 · Cited by 2
Real-World Impact of Metformin on Outcomes in Patients with Deficient DNA Mismatch Repair and Microsatellite Instability (dMMR/MSI) Colorectal Cancer Treated with Immune Checkpoint Inhibitors
Gupta, G., Sadeghipour, N., Bicer, F., Elliott, A., Hinton, A. C., Lou, E., Vanderwalde, A. M., Özlük, A. A., Khushman, M. M., Malla, M., et al. (2025) · Cancers · doi:10.3390/cancers17243944 · Cited by 2
Association between serum uric acid levels and clinical outcomes of immunotherapy in advanced colorectal cancer patients
Fan, S., Shao, M., & Ma, W. (2026) · BMC Cancer · doi:10.1186/s12885-025-15431-y · Cited by 2
Nanoparticle-mediated radiosensitization in colorectal cancer radiation therapy: A narrative review on mechanisms, clinical translation, and future perspectives
Taghvimi, S., Fard, E. S., Baghrobehbahani, A., Shafiee, M., Zarezadeh, V., Mamaghani, M. P., Nazarian, M., Chegeni, N., Movahedpour, A., Mousavi, P., et al. (2026) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2026.112486 · Cited by 2
The Evolving Role for Repeat Molecular Testing in Metastatic Colorectal Cancer
Kendsersky, N. D., Erlick, M. R., Chen, E., & Kennecke, H. F. (2026) · Cancers · doi:10.3390/cancers18061007 · Cited by 2
Nivolumab plus ipilimumab and cobimetinib in previously treated microsatellite-stable/DNA mismatch repair-proficient metastatic colorectal cancer: the phase II CheckMate 142 trial
Overman, M. J., McCraith, S. M., He, B., Jin, L., Lei, M., Yao, J., & Morse, M. A. (2026) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2026.100334 · Cited by 2
Self-citation
Targeting the tumor microenvironment for sensitization of colorectal cancer to chemotherapy and radiotherapy
Wu, J., & Zhang, L. (2026) · Pathology - Research and Practice · doi:10.1016/j.prp.2026.156480 · Cited by 2
Inflammation and Colorectal Cancer Pathogenesis: Molecular, Immunological, and Environmental Features for Therapy Response and Resistances
Seliger, B., Mantke, R., Naß, N., Dammermann, W., Ocvirk, S., Kah, J., Kalinski, T., & Massa, C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104299 · Cited by 3
Chinese guidelines for the diagnosis and comprehensive treatment of colorectal liver metastasis (2025 Edition)
Fan, J., Gu, J. F., Jia, B., Li, J., Qin, X., Wang, X., Xu, J., Xu, R., Ye, Y., 张苏展, et al. (2026) · Clinical Cancer Bulletin · doi:10.1007/s44272-026-00062-6 · Cited by 2
Immune Checkpoint-Based Therapies in Colorectal Cancer—Current Approaches and Future Perspectives
Nakielska, K., Plewka, J., & Lenart, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27104628 · Cited by 2
Immune checkpoint inhibitors in dMMR-MSI-H colorectal cancer: rationale, progress and prospects
Xu, G., Liang, D., Li, L. S., Cheng, J., & Wang, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1828717 · Cited by 2
Clinical complete response to serplulimab plus bevacizumab and chemotherapy in MSS/KRAS-mutant metastatic sigmoid colon adenocarcinoma: a case report and literature review
Luo, Q., Zhang, H., Di, B., Liu, Y., Lei, Y., Liu, H., Wang, J., & Luo, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1740803 · Cited by 2
The DNA damage response and cancer immunotherapy
Sheng, H., & Li, G. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00958-4 · Cited by 3
A new immunotherapy regimen in metastatic colon cancer: implications for palliative practice
Nicolson, N. G., & Johnston, F. M. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-22-1155 · Cited by 2
Precision Medicine in the Era of Genetic Testing: Microsatellite Instability Evolved
Ioffe, D., McSweeny, M. J., & Hall, M. J. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1770385 · Cited by 2
Treatment of Microsatellite-Unstable Rectal Cancer in Sporadic and Hereditary Settings
Anderson, C. E., & Liska, D. (2023) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0043-1770717 · Cited by 2
Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy
Collo, G. D., & Kamga, P. T. (2023) · Cancers · doi:10.3390/cancers15184503 · Cited by 2
Advancements in immunotherapy research for colorectal cancer based on microsatellite status
Shuai, X. I. A. O., XiGuang, C. H. E. N., & XuYu, Z. U. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0103 · Cited by 2
Colorectal Cancer Biomarkers Discovery Approach: A Proteomic and Genomic Perspective
Al-Zahrani, M. H. (2023) · Journal Of Biochemical Technology · doi:10.51847/gvy1i4x9bu · Cited by 2
Rational therapeutic targets with biomolecular liquid-liquid phase separation regulating synergy: A pan-cancer analysis
Sun, S., Wang, W., Li, G., Xiao, M., Peng, M., Cai, J., Wang, Z., Yang, Q., & He, X. (2023) · PLoS ONE · doi:10.1371/journal.pone.0287574 · Cited by 2
Cross-trial comparisons for the adjuvant treatment of MSI colorectal cancer: dare to dream the future scenarios.
Pastorino, A., Catalano, F., Zalcberg, J. R., & Sobrero, A. F. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113538 · Cited by 2
Comprehensive Landscape of BRAF Variant Classes, Clonalities, and Co-Mutations in Metastatic Colorectal Cancer Using ctDNA Profiling
Johnson, B., Morris, V. K., Wang, X., Dasari, A. N., Raghav, K. P. S., Shen, J. P., Lee, M. S., Huey, R. W., Parseghian, C. M., Willis, J. A., et al. (2024) · Cancers · doi:10.3390/cancers16040737 · Cited by 2
Self-citation
The efficacy-associated biomarkers for immune checkpoint inhibitors in gastrointestinal cancer: a literature review
Zhao, P., Jin, R. F., Zhao, B., Han, L. K., Chen, W., Hao, N., Cui, Y., Madan, A., Awosika, J. A., Lloyd, S. A. J., et al. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-843 · Cited by 3
Case report: Microsatellite instability determination is not always black and white in Lynch syndrome diagnosis
Rodriguez, J. E., Vasseur, D., Bani, M. A., Cabaret, O., Cotteret, S., Muleris, M., Golbarg, V., Malka, D., Pudlarz, T., Caron, O., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1396869 · Cited by 2
Immune check point inhibitors in BRAF mutated metastatic colorectal cancer: A review
Colombo, A., Cordio, S. S., & Porretto, C. M. (2024) · International Journal of Gastrointestinal Intervention · doi:10.18528/ijgii240030 · Cited by 2
Deciphering the Dilemma: Choosing the Optimal Total Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer
Manriquez-Alegria, E., Solé, S., Silva, J., Hermosilla, J. P., Romero, R., & Quezada-Díaz, F. (2024) · Current Oncology · doi:10.3390/curroncol31080320 · Cited by 2
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
Trembath, H. E., Yeh, J. J., & Lopez, N. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-61238-1_15 · Cited by 3
Severe Lymphopenia Predicts Poorer Survival in Patients With Rectal Cancer Undergoing Neoadjuvant Chemoradiation
Kim, D. W., Lee, G. C., Cai, E., Ryan, D. P., Parikh, A. R., Allen, J. N., Giantonio, B. J., Berger, D. L., Kunitake, H., Ricciardi, R., et al. (2025) · The Cancer Journal · doi:10.1097/ppo.0000000000000749 · Cited by 2
TRANSMIT: Utilizing discarded livers from donors with a history of cancer for patients lacking access to standard allocation - A compassionate use exploratory study
Koch, D. T., Schirren, M., Jacobi, S. J., Lange, C. M., Werner, J., Koliogiannis, D., & Guba, M. O. (2025) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2025.101465 · Cited by 2
Case Report: A long-term response of immunotherapy combined with anti-angiogenesis therapy in a patient with dMMR metastatic colorectal cancer after ICI failure
Huang, Q., Zheng, X., & Xu, W. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1553380 · Cited by 2
Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples
Xia, X., Du, W., & Gou, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-03684-3 · Cited by 2
Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing
Huo, L., Liang, P., Duan, Y., Xu, Y., Jianhua, T., Lv, Q., & Feng, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1590319 · Cited by 2
Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis
Iyer, K. A., Tenchov, R., Ivanov, J. M., & Zhou, Q. A. (2025) · ACS Omega · doi:10.1021/acsomega.5c00693 · Cited by 2
Highlights from the 2022 ASCO gastrointestinal cancer symposium: An overview by the EORTC gastrointestinal tract cancer group
Sclafani, F., Fontana, E., Wyrwicz, L. S., Wagner, D., Valle, J. W., Smyth, E. C., Peeters, M., Obermannova, R. L., Neuzillet, C., Lutz, M. P., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.04.001 · Cited by 2
Neue medikamentöse Konzepte bei Patienten mit kolorektalen Karzinomen und Mikrosatelliteninstabilität
Vangala, D., & Nilius‐Eliliwi, V. (2023) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2012-4047 · Cited by 2
Immuntherapie in der Hepatogastroenterologie: Wirkung und Nebenwirkung
Krimmel, L., Quante, M., & Bengsch, B. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1919-8494 · Cited by 2
Case report: A combined immunotherapy strategy as a promising therapy for MSI-H colorectal carcinomas with multiple HPD risk factors
Zhang, J., Yang, L., Kong, F., Wu, D., Hu, B., Yang, J., He, J., & Liu, L. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1051034 · Cited by 2
Case report: long-term sustained remission in a case of metastatic colon cancer with high microsatellite instability and KRAS exon 2 p.G12D mutation treated with fruquintinib after local radiotherapy: a case report and literature review
Wang, R., Cong, D., Bai, Y., & Zhang, W. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1207369 · Cited by 2
Immunotherapy for Unresectable Small Bowel Adenocarcinoma: A Case Series
Sugiyama, K., Owaki, S., Sato, M., Shiraishi, K., Kato, K., & Kitagawa, C. (2023) · In Vivo · doi:10.21873/invivo.13469 · Cited by 2
Crossing survival curves of KEYNOTE-177 illustrate the rationale behind combining immune checkpoint inhibition with chemotherapy – Authors' reply
André, T., Diaz, L. A., & Shiu, K. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00299-6 · Cited by 2
The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisPreprint
Adrianto, A. A., Riwanto, I., Sadhana, U., Paramita, D. K., Setyawan, H., Tjandra, K. C., Respati, D. R. P., Rampengan, D. D. C. H., Ramadhan, R. N., Jangkang, G. G., et al. (2024) · medRxiv · doi:10.1101/2024.07.02.24309865 · Cited by 2
How could γδ T cells change the treatment landscape for colorectal cancers?
Blanco-Domínguez, R., & Mensurado, S. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2572962 · Cited by 2
Short-course radiotherapy as part of total neoadjuvant therapy for locally advanced rectal cancer – a new standard?
Suwiński, R., Zeman, M., Dębosz-Suwińska, I., & Idasiak, A. (2022) · Nowotwory Journal of Oncology · doi:10.5603/njo.a2022.0056 · Cited by 1
The genomics of liver metastases from colon and rectal cancer: An Invited Commentary (invitation from Lee Ocuin, MD and Kevin Behrns, MD) for the special issue of “Management of Advanced Primary and Secondary Liver Malignancies”
Schwantes, I. R., & Mayo, S. C. (2023) · Surgery · doi:10.1016/j.surg.2023.03.021 · Cited by 1
Interim results of neoadjuvant immunotherapy with prolgolimab in patients with locally advanced MSI / dMMR colorectal cancer
Zagidullina, A. A., Kuznetsova, O. A., Fedyanin, M. Y., Mamedli, Z. Z., Алиев, В. А., Polynovskiy, A. V., Malikhova, O. A., Александрович, К. И., Строганова, А. М., & Tryakin, A. A. (2024) · Malignant tumours · doi:10.18027/2224-5057-2024-013 · Cited by 1
Overview of systemic treatment and toxicity in cancer patients
Song, M. M., Mandel, J. J., & Newton, H. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15663-2.00027-4 · Cited by 1
Reassessing the Prognostic Value of Lymph Node Metastasis in Deficient Mismatch Repair Colorectal Cancer
Ye, Z., Luo, D., Chen, F., Chen, J., Shan, Z., Weng, J., Zhang, Y., Li, Q., & Li, X. (2025) · Current Oncology · doi:10.3390/curroncol32050254 · Cited by 1
Homologous recombination deficiency and immunotherapy response in microsatellite-stable colorectal cancer: Evidence from a cohort study in China
Feng, H., Zhao, L., Xu, Z., Xie, Q.-F., Deng, H., Jiang, Y., & Liu, H. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i5.102767 · Cited by 2
NEXUS: a phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Choo, J. R. E., Jeraj, S. N., Sundar, R., Yong, W. P., Lee, M., Huang, Y., Asokumaran, Y., Chan, G. H. J., Ngoi, N. Y. L., Wong, A. L. A., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251339930 · Cited by 1
Interpretable combined models for predicting treatment response and hematologic toxicity in locally advanced gastric cancer treated with PD-1 blockade and neoadjuvant chemotherapy
Wei, Y., Zhu, Y., Dong, Q., Wang, W., Yu, T., Zhang, J., & Dong, Y. (2025) · European Journal of Radiology · doi:10.1016/j.ejrad.2025.112256 · Cited by 1
Consistency and Heterogeneity of Microsatellite Instability (MSI) Status in Paired Biopsy and Surgical Specimens of Colorectal Cancer: A Necessity for MSI Reassessment After Treatment?
Tang, Y., Cui, W., Shi, S., Sun, L., Yan, L., Wei, B., Liu, F., Xi, Y., Xie, B., & Zhang, Z. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00010 · Cited by 1
Postpartum colonic squamous cell carcinoma with a BRAFV600E mutation: a case report
Wang, Q., Zhang, H., Yao, W.-R., Zhang, X., Tong, H., & Liu, L. (2025) · Journal of Medical Case Reports · doi:10.1186/s13256-025-05491-w · Cited by 1
Simple porphyrin nanoparticles for combined photo-immunotherapy of colorectal cancer
Sun, H., Fan, Z., Pei, Q., Xie, Z., Zhang, T., & Ma, C. (2025) · Biomaterials Advances · doi:10.1016/j.bioadv.2025.214466 · Cited by 1
Neoadjuvant combination immunotherapy for colorectal cancer: clinical and molecular predictors of pathological complete response and safety assessment
Li, Y., Zhuang, M., Mei, S., Hu, G., Zhao, W., Qiu, W., Wang, X., & Tang, J. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04268-1 · Cited by 1
Development of the rationale of a personalized cancer vaccine based on the in situ vaccine effect of radiotherapy: a mechanistic study of the POLARSTAR trial
Pang, K., Sun, P., Liu, X., Yang, D., Zhao, P., Huang, Y., Cao, S., Gao, Y., Chen, G., Yu, H., et al. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04229-3 · Cited by 1
Targeting CAD with a tumor microenvironment-responsive nano-heterojunction for synergistic induction of cuproptosis and inhibition of colorectal cancer progression
Xiang, Y., Liao, Y., Mi, Y., Zhai, Z., Zhao, W., Zhang, Y., Chen, Z., Li, C., Wang, X., Zhang, S., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03858-1 · Cited by 1
Механизмы резистентности к иммунотерапии при MSI фенотипе
Федянин, М. Ю. (2025) · Malignant tumours · doi:10.18027/2224-5057-2025-15-3s1-11-30 · Cited by 1

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, K. Y. M., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.11 · Cited by 59
Self-citation
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270
Self-citation
SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142
André, T., Lonardi, S., Wong, K. Y. M., Lenz, H., Gelsomino, F., Aglietta, M., Morse, M. A., Cutsem, E. V., McDermott, R., Hill, A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.05.051 · Cited by 9
Self-citation
Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079
Self-citation
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
Lenz, H., Lonardi, S., Zagonel, V., Cutsem, E. V., Limón, M. L., Wong, M. K., Hendlisz, A., Aglietta, M., Alfonso, P. G., Neyns, B., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4040 · Cited by 43
Self-citation

See all

Authors: Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., Dragovich, T., Shah, U., Abdullaev, S., Gricar, J., Ledeine, J.-M., Overman, M. J., & Lonardi, S.
Affiliations: USC Norris Comprehensive Cancer Center (US)
University Hospitals Gasthuisberg/Leuven and KU Leuven, Leuven, Belgium
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Westmead Hospital (AU)
Institut Jules Bordet (BE)
Candiolo Cancer Institute (IT)
Hospital General Universitario Gregorio Marañón (ES)
Universitair Ziekenhuis Brussel (BE)
University of Modena and Reggio Emilia (IT)
Vanderbilt University (US)
Banner MD Anderson Cancer Center (US)
Lehigh Valley Cancer Institute, Allentown, PA
Bristol-Myers Squibb (United States) (US)
The University of Texas MD Anderson Cancer Center (US)
Istituto Oncologico Veneto (IT)
ORCID: Lenz, Heinz-Josef
Van Cutsem, Eric
Luisa Limon, Maria
Hendlisz, Alain
Aglietta, Massimo
Neyns, Bart
Cardin, Dana B.
Overman, Michael James
Lonardi, Sara
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2022-01-10
Volume: 40
Issue: 2
Pages: 161-170
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.21.01015
OpenAlex: W3206775306
Semantic Scholar: 2e81a9ea94ac646baf31c284ca8497f8b3df6f0e
Cited by: 728
References: 30
Citations by year: 2026: 125 · 2025: 148 · 2024: 182 · 2023: 173 · 2022: 93
FWCI: 41.26
Type: journal article
Language: en
Open access: green
biblio.vub.ac.be
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
VUBIR (Vrije Universiteit Brussel) (submittedVersion)
Lirias (submittedVersion)
Funders: Bristol-Myers Squibb
Agilent Technologies (PD-L1 IHC 28-8)
Ono Pharmaceutical
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: nivolumab, ipilimumab, metastatic colorectal cancer, microsatellite instability-high, mismatch repair deficiency, first-line therapy, immune checkpoint inhibitors, combination immunotherapy, objective response rate, progression-free survival, treatment-related adverse events
MeSH terms: Ipilimumab, Nivolumab, Progression-Free Survival, Immune Checkpoint Inhibitors, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Colorectal Neoplasms, Disease Progression, Microsatellite Instability, DNA Mismatch Repair, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks